Arcus Biosciences Inc

For the period ended Dec 31, 2023. Filed Feb 21, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 21, 2024

RCUS$18.95+3.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

December 31, 2023 and 2022

(In millions, except per share amounts)

	December 31,
	2023	2022
ASSETS
Current assets:
Cash and cash equivalents	$127	$206
Marketable securities	632	803
Receivable from collaboration partners ($20 and $39 from a related party)	38	39
Prepaid expenses and other current assets	34	19
Total current assets	831	1,067
Long-term marketable securities	107	129
Property and equipment, net	51	35
Other noncurrent assets ($6 and $2 from a related party)	106	114
Total assets	$1,095	$1,345
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$17	$20
Deferred revenue ($84 and $97 to a related party)	91	97
Other current liabilities	76	76
Total current liabilities	184	193
Deferred revenue, noncurrent ($291 and $355 to a related party)	307	355
Other noncurrent liabilities	142	140
Commitments (Note 16)
Stockholders’ equity:
Common stock and additional paid-in capital: $0.0001 par value per share; 400.0 shares authorized; 75.5 shares in 2023 and 72.9 shares in 2022 issued and outstanding	1,311	1,206
Accumulated deficit	(849)	(542)
Accumulated other comprehensive loss	—	(7)
Total stockholders’ equity	462	657
Total liabilities and stockholders’ equity	$1,095	$1,345

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.